Nightfood Holdings Inc. (OTCQB: NGTF), operating through its TechForce Robotics subsidiary, has announced the advancement of Phase 2 objectives under its joint development collaboration with Oncotelic Therapeutics (OTCQB: OTLC). The key development is the deployment of PUR-E, an autonomous clean room support robot, within SAPU Bio’s OEB-5 sterile injectable cGMP facility. This move expands the initiative beyond Phase 1 materials logistics operations and into sterile manufacturing and clean room environments, where TechForce and Oncotelic are evaluating robotics, automation and AI-driven technologies to support regulated pharmaceutical workflows.
PUR-E joins TechForce’s LIM-E autonomous GMP support robot at the SAPU Bio facility. Together, these systems are being used to assess opportunities in sterile manufacturing operations, electronic batch record processes and other cGMP activities. According to the companies, the initiative is part of a broader effort to develop robotics and automation solutions for pharmaceutical manufacturing, biotechnology and life sciences environments. PUR-E operates as part of TechForce’s Robotics-as-a-Service Provider (RaaSP) platform.
This deployment is significant for the pharmaceutical industry, which faces increasing pressure to improve efficiency, ensure regulatory compliance, and address labor challenges. By introducing autonomous robots into sterile environments, companies can reduce human error, enhance consistency, and maintain strict clean room standards. The use of AI-driven technologies also enables real-time monitoring and data collection, which can improve batch record accuracy and traceability.
For Nightfood Holdings, this advancement supports its broader strategy to become a key player in pharmaceutical automation. The company, through TechForce Robotics, focuses on developing and deploying intelligent automation solutions across multiple industries, including hospitality, foodservice, commercial, and laboratory settings. Its Robotics-as-a-Service model provides customers with flexible, scalable automation solutions while generating recurring revenue opportunities.
The collaboration with Oncotelic Therapeutics, a company focused on developing therapies for cancer and other diseases, adds credibility and domain expertise to the initiative. As the pharmaceutical industry increasingly adopts automation to meet regulatory demands and improve operational efficiency, partnerships like this could accelerate the integration of robotics into critical manufacturing processes.
Investors and industry leaders should watch this development closely, as successful deployment in sterile manufacturing could open new markets for TechForce Robotics and set a precedent for automation in highly regulated environments. The full press release is available at https://ibn.fm/mXU1p. For more updates on Nightfood Holdings, visit the company’s newsroom at http://ibn.fm/NGTF.
